CALCULATIONS, COLOURS & SYMBOLS DEFINED

**SYMBOLS**
- Canada (We are Canadian)
- Non-formulary in Saskatchewan
- Exception Drug Status (EDS) in Saskatchewan (SK) (1-800-662-2549)
- Prior approval required by NHIB. Coverage for eligible First Nations & Inuit (1-800-580-0950); Q= NHIB Palliative Care Formulary
- Covered by NHIB. Found on the OTC charts (pages 139-142) & identified ONLY for those drugs which have SK Formulary restrictions such as EDS or non-formulary status.
- On Saskatchewan Cancer Agency Formulary
- Health Canada Official Indication
- Refrigerate
- Warfarin interactions on the herbal chart
- Adverse Event
- Combination product
- Drug interaction
- Contraindication
- Monitoring
- Retail Cost to Consumer based on acquisition cost, markup & dispensing fee in Saskatchewan. Lowest generic price used where available.
- Tablet is scored. Appears as superscript, e.g. 25 mg tablet.
- Porphyria
- Concern if drug or herbal is given Pre-Op
- Generic drug available
- Female
- Neutral
- Inhibitor
- Tastes good
- Avoid if patient has soybean & peanut allergy
- Check our website for On-line extras (www.RxFiles.ca)
- $ on STOPP/START Criteria 2014; $ on Beers Criteria 2019
- Dose may be required for liver dysfunction
- Dose required for renal dysfunction 1. If [1] drug ≥ 75% renal excretion 2. toxic if accumulates 3. an active metabolite requiring dose adjustment. [CrCl<60mL/min indicates impaired renal function]

**Calculations**
- Ideal Body Weight (kg) [IBW]
  
  \[
  \text{Males} = 50kg + 0.906 \times (\text{Height in cm} - 152.4cm); \text{Females} = 45.5kg + 0.906 \times (\text{Height in cm} - 152.4cm)
  \]
- Adjusted Body Weight (kg) [ABW]
  
  \[
  = \text{(Ideal body weight (IBW)) + 0.4 (Actual body weight -IBW)}
  \]
- Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI]
- Creatinine Clearance (mL/min) [CrCl]
  
  \[
  (\text{mL/min}: \text{Male} = (\text{140-ago}) \times \text{ABW weight in kg} / (\text{Scr in umol/L} \times 0.814); \text{Female} = 0.85 \times \text{CrCl} \text{ male}; \text{Or:}}
  \]
  \[
  (\text{mL/sec/70kg}) = ((\text{140-ago}) \times 1.5 \times [\text{0.85 if female}]/(\text{Scr in umol/L}))
  \]
- Modification of Diet in Renal Disease [MDRD]
  
  eGFR = accurate, but need website or app with MedCalc to do the calculation. www.hdcn.com www.kidney.org

**Formulary Related Symbols**

<table>
<thead>
<tr>
<th><strong>Creatinine Clearance (mL/min)</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI]</strong></td>
</tr>
<tr>
<td><strong>Most accurate for CKD estimation:</strong> <a href="http://www.kidney.org/professionals/kdoq/gfr_calculator.cfm">http://www.kidney.org/professionals/kdoq/gfr_calculator.cfm</a></td>
</tr>
<tr>
<td><strong>Creatinine Clearance (mL/min) [CrCl]</strong></td>
</tr>
<tr>
<td><strong>Modification of Diet in Renal Disease [MDRD]</strong></td>
</tr>
</tbody>
</table>

**Drug Interactions**

<table>
<thead>
<tr>
<th><strong>DRUGS IN PREGNANCY &amp; LACTATION RISK CATEGORIES</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pregnancy [P] (subscript denotes trimester specific info)</strong></td>
</tr>
<tr>
<td><strong>Safe [Safe]</strong></td>
</tr>
<tr>
<td>• Compatible in pregnancy (unproven associations possible)</td>
</tr>
<tr>
<td><strong>Likely Safe [Likely Safe]</strong></td>
</tr>
<tr>
<td>• No (limited) human data – probably compatible</td>
</tr>
<tr>
<td>• Compatible = maternal benefit &gt;&gt; embryo-fetal risk</td>
</tr>
<tr>
<td>• Human data suggest low risk</td>
</tr>
<tr>
<td><strong>Caution [Caution]</strong></td>
</tr>
<tr>
<td>• Human, and or animal, data suggest risk</td>
</tr>
<tr>
<td>• Potential risk in specific trimester(s), as indicated by ‘x’</td>
</tr>
<tr>
<td><strong>Contraindicated [Contraindicated]</strong></td>
</tr>
<tr>
<td>• Contraindicated in pregnancy</td>
</tr>
<tr>
<td>• Contraindicated in specific trimester(s), as indicated by ‘x’</td>
</tr>
</tbody>
</table>

**COLOURS USED WITHIN THE CHARTS**

<table>
<thead>
<tr>
<th><strong>Yellow highlights</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CLINICAL DIFFERENCES, PRACTICE GAPS &amp; COMMON 7s</strong></td>
</tr>
<tr>
<td><strong>Green shading usually indicates HERBAL/LIFESTYLE related</strong></td>
</tr>
<tr>
<td><strong>Light Blue shading usually indicates PEDIATRIC related</strong></td>
</tr>
<tr>
<td><strong>Dark Blue shading usually indicates ADOLESCENT related</strong></td>
</tr>
<tr>
<td><strong>Tan shading usually indicates GERIATRIC/older adult related</strong></td>
</tr>
<tr>
<td><strong>Purple shading usually indicates OVERVIEW/GUIDELINE approach</strong></td>
</tr>
<tr>
<td><strong>Red shading usually indicates official FDA black box or HC warning</strong></td>
</tr>
<tr>
<td><strong>Purple script usually indicates TRADE NAMES (© implied)</strong></td>
</tr>
<tr>
<td><strong>Blue script usually indicates MAJOR TRIALS</strong></td>
</tr>
<tr>
<td><strong>Pink script usually indicates PREGNANCY &amp; LACTATION related</strong></td>
</tr>
<tr>
<td><strong>Gray script usually indicates DISCONTINUED drug</strong></td>
</tr>
</tbody>
</table>

**Abbreviations**

<table>
<thead>
<tr>
<th><strong>WHO Essential Medicines List</strong></th>
</tr>
</thead>
</table>

**Disclaimer**

The content of this book represents the research, experience and opinions of the authors and not those of the Board of Administration or University of Saskatchewan. Neither the authors, nor University of Saskatchewan, nor any other party who has been involved in the preparation or publication of this work warrants or represents that the information contained herein is accurate or complete, and they are not responsible for any errors or omissions or for the result obtained from the use of such information. Any use of the book will imply acknowledgment of this disclaimer and release any responsibility of U of S, its employees, servants or agents. Readers are encouraged to confirm the information contained herein with other sources. © Copyright 2019 - University of Saskatchewan, College of Pharm.